Form 13-F position report

CORCEPT THERAPEUTICS INC

Reported by FAS Wealth Partners

CORT CUSIP 218352102 Manager CIK 0001596957

Reported 317,950 shares, down 6,926 (2.1%) from the prior quarter.

Reported value 29.7%; share count -2.1% vs. the prior quarter.

Reduced
% of reported 13F value 1.78% This manager · Q3 2026
Shares 317,950 Quarter-end amount reported
Reported value $36,637,379 Fair value at quarter end
Consecutive quarters held 27 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 5650000
2022-03-31 6522000
2022-06-30 7129000
2022-09-30 7681000
2022-12-31 6220466
2023-03-31 6606864
2023-06-30 6914655
2023-09-30 8466766
2023-12-31 10078252
2024-03-31 7843738
2024-06-30 10259433
2024-09-30 14612864
2024-12-31 15580941
2025-03-31 34296040
2025-06-30 22198289
2025-09-30 25624309
2025-12-31 10788627
2026-03-31 12994735
2026-06-30 28247969
2026-09-30 36637379

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for CORCEPT THERAPEUTICS INC held by FAS Wealth Partners.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 317,950 -6,926 (-2.1%) 1.78% $36,637,379 2026-11-16
Q2 2026 Added 324,876 +2,506 (0.8%) 1.47% $28,247,969 2026-07-29
Q1 2026 Added 322,370 +12,352 (4.0%) 0.81% $12,994,735 2026-06-10
Q4 2025 Added 310,018 +1,700 (0.6%) 0.7% $10,788,627 2026-02-18
Q3 2025 Added 308,318 +5,889 (1.9%) 1.74% $25,624,309 2025-10-29
Q2 2025 Added 302,429 +2,166 (0.7%) 1.64% $22,198,289 2025-08-14
Q1 2025 Reduced 300,263 -8,944 (-2.9%) 2.8% $34,296,040 2025-05-05
Q4 2024 Reduced 309,207 -6,542 (-2.1%) 1.31% $15,580,941 2025-02-14
Q3 2024 Reduced 315,749 -23 (0.0%) 1.16% $14,612,864 2024-10-17
Q2 2024 Added 315,772 +4,389 (1.4%) 0.89% $10,259,433 2024-07-29
Q1 2024 Added 311,383 +1,092 (0.4%) 0.7% $7,843,738 2024-04-29
Q4 2023 Reduced 310,291 -473 (-0.2%) 0.96% $10,078,252 2024-01-23
Q3 2023 Reduced 310,764 -7 (0.0%) 0.91% $8,466,766 2023-10-23
Q2 2023 Added 310,771 +5,745 (1.9%) 0.87% $6,914,655 2023-08-08
Q1 2023 Reduced 305,026 -1,250 (-0.4%) 0.72% $6,606,864 2023-05-11
Q4 2022 Added 306,276 +6,700 (2.2%) 0.7% $6,220,466 2023-02-01
Q3 2022 Reduced 299,576 -204 (-0.1%) 0.85% $7,681,000 2022-10-20
Q2 2022 Added 299,780 +10,155 (3.5%) 0.75% $7,129,000 2022-08-02
Q1 2022 Added 289,625 +4,283 (1.5%) 0.61% $6,522,000 2022-05-04
Q4 2021 Reduced 285,342 -300 (-0.1%) 0.52% $5,650,000 2022-02-11
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

537 managers reported CORCEPT THERAPEUTICS INC for Q3 2026.

Managers reporting CORCEPT THERAPEUTICS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
BlackRock Inc Reduced 10,195,060 -2,236,963 0.02% $1,174,776,762 9 qtrs
INGALLS & SNYDER LLC Reduced 7,667,798 -266,709 22.58% $883,560,000 16 qtrs
RENAISSANCE TECHNOLOGIES LLC Reduced 4,850,083 -411,545 0.76% $558,875,064 47 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Reduced 4,777,065 -267,573 0.02% $550,461,200 3 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 4,353,398 +180,916 0.01% $501,642,052 3 qtrs
Parallel Advisors LLC Reduced 3,902,544 -59,633 6.06% $449,690,145 30 qtrs
AQR CAPITAL MANAGEMENT LLC Added 3,640,962 +1,058,401 0.12% $419,548,029 51 qtrs
FMR LLC Added 3,488,722 +151,104 0.02% $402,005,468 39 qtrs
STATE STREET CORPORATION Reduced 3,104,960 -174,421 0.01% $357,784,541 54 qtrs
GEODE CAPITAL MANAGEMENT LLC Reduced 2,335,372 -196,826 0.01% $269,156,621 54 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 16, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
0
Shared
0
None
317,950

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.